CIK 0001437402 · Large accelerated filer
ARDELYX, INC.
Sign in to watch- Ticker
- ARDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 510-745-7047
- Business address
- 34175 ARDENWOOD BLVD., FREMONT, CA, 94555
- Former names
- NTERYX INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $486,197
- in 8 filings
Net −$486,197. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- RAAB MICHAEL −$226K President & CEO sold 3% of stake
- Bishop John E −$76K See Remarks sold 6% of stake
- Brady James Parker −$58K Chief Human Resources Officer sold 6% of stake
- Williams Laura A −$41K Chief Patient Officer sold 3% of stake
- Foster Eric Duane −$33K Chief Commercial Officer sold 2% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-16 | MOTT DAVID M Director | Grant or award | +20,282 | 3,323,200 | ||
| 2026-06-16 | MOTT DAVID M Director | Grant or award | +26,455 | 3,349,655 | ||
| 2026-06-16 | MOTT DAVID M Director | Grant or award · Stock Option (Right to Buy) | +39,715 | 39,715 | ||
| 2026-06-15 | RAAB MICHAEL President & CEO | Option exercise 10b5-1 | +20,833 | $0.99 | $21K | 1,740,866 |
| 2026-06-15 | RAAB MICHAEL President & CEO | Sale 10b5-1 | −41,666 | $5.67 | $236K | 1,699,200 |
| 2026-06-15 | RAAB MICHAEL President & CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,833 | 311,668 | ||
| 2026-05-21 | Hohenleitner Susan Chief Financial Officer | Sale | −1,455 | $6.27 | $9K | 229,078 |
| 2026-05-21 | Brady James Parker Chief Human Resources Officer | Sale | −1,846 | $6.27 | $12K | 261,066 |
| 2026-05-21 | Reilly Joseph James See Remarks | Sale | −2,683 | $6.27 | $17K | 149,107 |
| 2026-05-21 | Reilly Joseph James See Remarks | Sale | −1,036 | $6.27 | $6K | 149,836 |
| 2026-05-21 | Foster Eric Duane Chief Commercial Officer | Sale | −3,166 | $6.27 | $20K | 422,804 |
| 2026-05-21 | Foster Eric Duane Chief Commercial Officer | Sale | −2,427 | $6.27 | $15K | 420,377 |
| 2026-05-21 | Foster Eric Duane Chief Commercial Officer | Sale | −2,405 | $6.27 | $15K | 417,972 |
| 2026-05-21 | Kelliher Mike Chief Business Officer | Sale | −2,900 | $6.27 | $18K | 361,766 |
| 2026-05-21 | Kelliher Mike Chief Business Officer | Sale | −1,870 | $6.27 | $12K | 359,896 |
| 2026-05-21 | Kelliher Mike Chief Business Officer | Sale | −2,478 | $6.27 | $16K | 357,418 |
| 2026-05-21 | Williams Laura A Chief Patient Officer | Sale | −1,503 | $6.27 | $9K | 434,579 |
| 2026-05-21 | Williams Laura A Chief Patient Officer | Sale | −2,157 | $6.27 | $14K | 432,422 |
| 2026-05-21 | Williams Laura A Chief Patient Officer | Sale | −1,911 | $6.27 | $12K | 430,511 |
| 2026-05-21 | Williams Laura A Chief Patient Officer | Sale | −1,418 | $6.27 | $9K | 429,093 |
Page 3 of 11 · 206 trades